» Articles » PMID: 31336903

PPARs As Nuclear Receptors for Nutrient and Energy Metabolism

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2019 Jul 25
PMID 31336903
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

It has been more than 36 years since peroxisome proliferator-activated receptors (PPARs) were first recognized as enhancers of peroxisome proliferation. Consequently, many studies in different fields have illustrated that PPARs are nuclear receptors that participate in nutrient and energy metabolism and regulate cellular and whole-body energy homeostasis during lipid and carbohydrate metabolism, cell growth, cancer development, and so on. With increasing challenges to human health, PPARs have attracted much attention for their ability to ameliorate metabolic syndromes. In our previous studies, we found that the complex functions of PPARs may be used as future targets in obesity and atherosclerosis treatments. Here, we review three types of PPARs that play overlapping but distinct roles in nutrient and energy metabolism during different metabolic states and in different organs. Furthermore, research has emerged showing that PPARs also play many other roles in inflammation, central nervous system-related diseases, and cancer. Increasingly, drug development has been based on the use of several selective PPARs as modulators to diminish the adverse effects of the PPAR agonists previously used in clinical practice. In conclusion, the complex roles of PPARs in metabolic networks keep these factors in the forefront of research because it is hoped that they will have potential therapeutic effects in future applications.

Citing Articles

Autophagy and the peroxisome proliferator-activated receptor signaling pathway: A molecular ballet in lipid metabolism and homeostasis.

Kiani P, Khodadadi E, Nikdasti A, Yarahmadi S, Gheibi M, Yousefi Z Mol Cell Biochem. 2025; .

PMID: 39891864 DOI: 10.1007/s11010-025-05207-0.


Triterpenoids from Chios Mastiha Resin Against MASLD-A Molecular Docking Survey.

Milosevic N, Milanovic M, Medic Stojanoska M, Tipmanee V, Smyrnioudis I, Dedoussis G Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852166 PMC: 11763944. DOI: 10.3390/cimb47010051.


Exploring the Functionality of the Krüppel-like Factors in Kidney Development, Metabolism, and Diseases.

Salmon-Cabrales I, de la Garza-Kalife D, Garcia-Gonzalez G, Estrada-Rodriguez A, Jimenez-Gutierrez M, Santoyo-Suarez M Life (Basel). 2025; 14(12.

PMID: 39768378 PMC: 11728015. DOI: 10.3390/life14121671.


A sulfonimide derivative of bezafibrate as a dual inhibitor of cyclooxygenase-2 and PPARα.

Ammazzalorso A, Tacconelli S, Contursi A, Hofling U, Cerchia C, Di Berardino S Front Pharmacol. 2024; 15:1488722.

PMID: 39660001 PMC: 11628281. DOI: 10.3389/fphar.2024.1488722.


Inhibition of the miR-1914-5p increases the oxidative metabolism in cellular model of steatosis by modulating the Sirt1-PGC-1α pathway and systemic cellular activity.

Porto-Barbosa T, Ramos L, Pansa C, Molica L, Malaspina O, Moraes K PLoS One. 2024; 19(11):e0313185.

PMID: 39514580 PMC: 11548759. DOI: 10.1371/journal.pone.0313185.


References
1.
Rubins H, Robins S, Collins D, Fye C, Anderson J, Elam M . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341(6):410-8. DOI: 10.1056/NEJM199908053410604. View

2.
Suh N, Wang Y, Williams C, Risingsong R, Gilmer T, Willson T . A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999; 59(22):5671-3. View

3.
Mehta R, Williamson E, Patel M, Koeffler H . A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst. 2000; 92(5):418-23. DOI: 10.1093/jnci/92.5.418. View

4.
Marrapodi M, Chiang J . Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Lipid Res. 2000; 41(4):514-20. View

5.
Leibowitz M, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J . Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett. 2000; 473(3):333-6. DOI: 10.1016/s0014-5793(00)01554-4. View